Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder.
J Affect Disord
January 2025
Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Department of Medicine, Duke University, Durham, NC, USA; Duke Institute of Brain Sciences, Duke University, Durham, NC, USA. Electronic address:
Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways.
View Article and Find Full Text PDFHigh Voltage Pulsed Radiofrequency Combined With Duloxetine on the Treatment of Glossopharyngeal Neuralgia.
J Craniofac Surg
December 2024
School of Anesthesiology, Shandong Second Medical University.
The incidence of glossopharyngeal neuralgia (GPN) is low, but the pain of GPN is severe and seriously affects the patient's life. We report a case with GPN, who had pain relief after treatment with high-voltage pulsed radiofrequency (PRF) combined with duloxetine. This case indicates that high-voltage PRF combined with duloxetine may be an effective approach for reducing pain in patients with GPN, and duloxetine may have a potential advantage for patients with evoked pain.
View Article and Find Full Text PDFOptimization of initial dosage of quetiapine in schizophrenic patients: effects of fluvoxamine or duloxetine coadministration.
Front Pharmacol
November 2024
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy and School of Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Objective: Although quetiapine has been approved for use in schizophrenic patients, its individualized dosage regimen remains unclear, especially with respect to drug-drug interactions (DDIs). Thus, we investigated the potential DDIs and optimal initial dosage of quetiapine in schizophrenic patients based on population pharmacokinetics (PPK).
Methods: Ninety-six schizophrenic patients treated with quetiapine were included to establish the PPK model, which also includes coadministration of multiple drugs.
INVESTIGATION OF THE EFFECT OF THE ONSET OF BRUXISM AS A RESULT OF EARLY ANTIDEPRESSANT USE.
Psychiatr Danub
August 2024
Kocaeli University, School of Medicine, Department of Psychiatry, Kocaeli.
Article Synopsis
- The study focuses on the effects of SSRIs and SNRIs, commonly prescribed antidepressants, on sleep disorders and bruxism (teeth grinding) among major depression patients.
- 125 patients were evaluated for bruxism after one week and then again after four weeks of using these medications.
- Results showed that while bruxism wasn't significantly impacted in the first week, an increase in sleep bruxism was observed in male patients by the fourth week, particularly linked to paroxetine and duloxetine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!